CYP Discussion 2022
- Thread starter zeeb0t
- Start date
Slymeat
Move on, nothing to see.
Trading halt waiting for release of results from DFU trial.
I believe this is the trial https://synapse.patsnap.com/blog/cy...tic-foot-ulcers-completes-patient-recruitment.
The date fits for 24 week follow-up.
I note the 10 week follow-up was positive.
”Initial results from the first 16 patients after a 10-week follow-up period have shown promising signs, with the CYP-006TK group experiencing an 87.6% median reduction in wound surface area, significantly higher than the 51.1% reduction observed in the control group.”
So hope for more positive news for a needed treatment of a condition that has dire consequences.
I believe this is the trial https://synapse.patsnap.com/blog/cy...tic-foot-ulcers-completes-patient-recruitment.
The date fits for 24 week follow-up.
I note the 10 week follow-up was positive.
”Initial results from the first 16 patients after a 10-week follow-up period have shown promising signs, with the CYP-006TK group experiencing an 87.6% median reduction in wound surface area, significantly higher than the 51.1% reduction observed in the control group.”
So hope for more positive news for a needed treatment of a condition that has dire consequences.
Slymeat
Move on, nothing to see.
News released now.
Results seem promising.
Actually, wound size DECREASING in the CYP-006TK group compared to wound size INCREASING in standard of care group, is extremely good news.
“The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no
participants withdrew from the trial due to adverse events, and no suspected serious adverse
reactions were reported.
• Importantly, the trial also generated positive efficacy data, indicating improved wound healing
for CYP-006TK compared to the standard of care control group.
• The mean1 change from baseline in wound surface area was:
o After 12 weeks, a decrease (improvement) of 181 mm2 in the CYP-006TK group, and an
increase (deterioration) of 355 mm2 in the standard of care control group.
o After 24 weeks (end of study), a decrease (improvement) of 261 mm2 in the CYP-006TK
group, and an increase (deterioration) of 62 mm2 in the standard of care control group.”
Results seem promising.
Actually, wound size DECREASING in the CYP-006TK group compared to wound size INCREASING in standard of care group, is extremely good news.
“The trial met its primary objective, with CYP-006TK found to be safe and well-tolerated – no
participants withdrew from the trial due to adverse events, and no suspected serious adverse
reactions were reported.
• Importantly, the trial also generated positive efficacy data, indicating improved wound healing
for CYP-006TK compared to the standard of care control group.
• The mean1 change from baseline in wound surface area was:
o After 12 weeks, a decrease (improvement) of 181 mm2 in the CYP-006TK group, and an
increase (deterioration) of 355 mm2 in the standard of care control group.
o After 24 weeks (end of study), a decrease (improvement) of 261 mm2 in the CYP-006TK
group, and an increase (deterioration) of 62 mm2 in the standard of care control group.”
Similar threads
